Beximco Pharma, a part of the Beximco Group, was recently awarded the prestigious Scrip Award in the category of ‘Best Company in an Emerging Market’; an award that seeks to reward exceptional R&D based pharmaceutical companies of emerging markets. The company’s Chief Operating Officer, Mr. Rabbur Reza, who was present at the 13th Annual Scrip Award ceremony held in London, accepted the award on behalf of the company.
With this, the company crossed another key milestone. Beximco Pharma is one of Bangladesh’s largest and most successful businesses. Committed to providing access to affordable drugs, the company has emerged as a generic drug manufacturing giant. The company today contributes towards a major chunk of the country’s medical needs. In addition, the exports of Beximco Pharma are majorly directed towards the Philippines, Europe, and the U.S.
With this, the company crossed another key milestone. Beximco Pharma is one of Bangladesh’s largest and most successful businesses. Committed to providing access to affordable drugs, the company has emerged as a generic drug manufacturing giant. The company today contributes towards a major chunk of the country’s medical needs. In addition, the exports of Beximco Pharma are majorly directed towards the Philippines, Europe, and the U.S.
This is the first time a Bangladeshi company has received the Scrip Award for operational excellence and robust growth in the global market. The Scrip Awards honor companies and individuals who demonstrate outstanding performance in the global pharmaceutical and biotech industry by recognizing the significance of their contributions towards healthcare.
Beximco Pharma has been in the forefront of almost every major development in the industry in the country. In 2003, the company was the first to introduce anti-retroviral (ARV) in Bangladesh. In 2016, the company became the first Bangladeshi company to receive approval of its products from health Canada and also the USA, the previous year. Crossing such key milestones, Sohail F Rahman and Salman F Rahman, Beximco’s founders, are positive on the future of Beximco not just in the domestic market, but also on a global scale. Topping the list of prominent Bangladeshi businessmen, the Beximco brothers are also much active in their efforts to uplift the social sector of the country. With its broad portfolio and presence in the global market, Beximco Pharma is hopeful of further expansion through its strategic partnerships, research, developmental initiatives and strong leadership.
Beximco Pharma has been in the forefront of almost every major development in the industry in the country. In 2003, the company was the first to introduce anti-retroviral (ARV) in Bangladesh. In 2016, the company became the first Bangladeshi company to receive approval of its products from health Canada and also the USA, the previous year. Crossing such key milestones, Sohail F Rahman and Salman F Rahman, Beximco’s founders, are positive on the future of Beximco not just in the domestic market, but also on a global scale. Topping the list of prominent Bangladeshi businessmen, the Beximco brothers are also much active in their efforts to uplift the social sector of the country. With its broad portfolio and presence in the global market, Beximco Pharma is hopeful of further expansion through its strategic partnerships, research, developmental initiatives and strong leadership.
Comments
Post a Comment